D2, but not D1 dopamine receptor agonists potentiate cannabinoid- induced sedation in nonhuman primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 3, 2000, Pages 952-959

  Meschler, Justin P ^a,b   Clarkson, Francis A ^a   Mathews, Patricia J ^a   Howlett, Allyn C ^a,b   Madras, Bertha K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVONANTRADOL; PERGOLIDE; QUINELORANE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; SEDATION;

ANIMALS; CANNABINOIDS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYPNOTICS AND SEDATIVES; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; PHENANTHRIDINES; QUINOLINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0034008670     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315-348.
2. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 241:521-526.
3. Bidaut-Russell M and Howlett AC (1991) Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J Neurochem 57:1769-1773.
4. Bonhaus DW, Chang LK, Kwan J and Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888.
5. Breivogel CS, Sim LJ and Childers SR (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282:1632-1642.
6. Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz JC and Sokoloff P (1997) D-3 receptor test in vitro predicts decreased cocaine self-administration in rats. NeuroReport 8:2373-2377.
7. Castellano C, Cabib S, Palmisano A, Di Marzo V and Puglisi-Allegra S (1997) The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors. Behav Pharmacol 8:707-712,
8. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR and Martin BR (1993) Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
9. Diana M, Melis M, Muntoni AI and Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 17:10269-10273.
10. Di Marzo V, Melck D, Bisogno T and De Petrocellis L (1998) Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 12:521-528.
11. Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelley ME, Naylor RJ, Owen DA and Wright A (1991) Preclinical pharmacology of ropinerole (SK&F 101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behav 38:147-154.
12. Ferguson SA, Felipa HN and Bowman RE (1996) Effects of acute treatment with dopaminergic drugs on open field behavior of adult monkeys treated with lead during the first year postpartum. Neurotoxicol Teratol 18:181-188.
13. Gfroerer JC and Brodsky MD (1993) Frequent cocaine users and their use of treatment. Am J Public Health 83:1149-1154.
14. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M and Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
15. Glass M and Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
16. Gnanalingham KK, Hunter AJ, Jenner P and Marsden CD (1995) Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease - the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology 117:403-412.
17. 1 dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 292:714-724.
18. Haney M, Foltin RW and Fischman MW (1998) Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology 37:15-24.
19. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
20. Hewlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR and Herkenham M (1990) The cannabinoid receptor: Biochemical, anatomical and behavioral characterization. Trends Neurosci 13:420-423.
21. Jain AK, Ryan JR, McMahon FG and Smith G (1981) Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 21: S320-S326.
22. 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 246:169-172.
23. 1 receptor knockout mice. Science (Wash DC) 283:401-404.
24. Levin FR, McDowell D, Evans SM, Brooks D, Spano C and Nunes EV (1999) Pergolide mesylate for cocaine abuse: A controlled preliminary trial. Am J Addict 8:120-127.
25. Leweke FM, Giuffrida A, Wurster U, Emrich HM and Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. NeuroReport 1:1665-1669.
26. Little PJ, Compton DR, Johnson MR, Melvin LS and Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247:1046-1051.
27. Maneuf YP, Crossman AR and Brotchie JM (1997) The cannabinoid receptor agonist WIN 55212-2 reduces D2, but not Dl, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 148:265-270.
28. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
29. McIlhenny HM, Mast RW, Johnson MR and Milne GM (1981) Nantradol hydrochloride: Pharmacokinetics and behavioral effects after acute and chronic treatment. J Pharmacol Exp Ther 219:363-369.
30. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME and Huff RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290:29-36.
31. Muller-Vahl KR, Kolbe H, Schneider U and Emrich HM (1998) Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502-506.
32. Pacheco MA, Ward SJ and Childers SR (1993) Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 603:102-110.
33. Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S1 Carter JH and Nutt JG (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45:736-741.
34. Rodriguez de Fonseca FR, Villanua MA, Munoz RM, San-Martin-Clark O and Navarro M (1995) Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendrocrinology 61:714-721.
35. Rosenzweig-Lipson S, Hesterberg P and Bergman J (1994) Observational studies of dopamine D1 and D2 agonists in squirrel monkeys. Psychopharmacology 116:9-18.
36. Smith KM and Cohen FL (1988) Compound narcolepsy: Development of biochemical imbalance. Int J Neurosci 42:229-252.
37. Tanda G, Pontieri FE and Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (Wash DC) 276:2048-2050.
38. Tsaioun K, Miller G and Madras BK (1999) Cannabinoid and dopamine interactions in the primate brain: Behavioral and cellular correlates. Soc Neurosci Abst 25:2214 1999.
39. van den Buuse M (1995) Differential effects of quinelorane and pergolide on behavior, blood pressure, and body temperature of spontaneously hypertensive rats and Wistar-Kyoto rats. Pharmacol Biochem Behav 50:389-397.
40. Vasquez C and Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280.
41. Witkin JM (1994) Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci Biobehav Rev 18:121-142.
42. Young AM, Katz JL and Woods JH (1981) Behavioral effects of levonantradol and nantradol in the rhesus monkey. J Clin Pharmacol 21:348S-360S.